Jim Tananbaum is the brain behind a successful healthcare company, Foresite Capital. Under his leadership, the company has been able to invest in over 70 different healthcare corporations. These companies have extensive experience in diagnostics, provision of medical services, genomic sequencing and biopharmaceuticals. The entrepreneur has taken it upon himself to provide healthcare-related companies and entrepreneurs with the much needed capital, connections and information.
Over the years, he has been passionate about the use computer science in the healthcare industry. Jim contends that Foresite means to harness the future of healthcare. Tananbaum says that he decided to establish the company after understanding that for a healthcare company to succeed, it requires adequate resources. To this end, Jim has been offering his services to entrepreneurs who render their services in the healthcare industry. By virtue of being in the industry for long, Jim Tananbaum has been seeking to comprehend all the information that talks about advancements in healthcare. This way, he is well positioned to know the areas that need more investment. Jim is able to determine the investments that guarantee the highest returns.
Today, he works closely with some of the leading healthcare companies, including Intarcia Therapeutics, Aimmune Therapeutics, 10x Genomics and Aerie Pharmaceuticals. Jim says that working with effective thought leaders in the industry has served to enhance his ideas. The shrewd entrepreneur posits that Foresite Capital is founded on the basis of helping different companies to make scientific discoveries that can have the greatest impact on healthcare.
Jim acknowledges that to him, family comes first. When he is not at home, he is busy networking and interacting with his friends. At work, Tananbaum spends time with his team discussing about the existing portfolios in his company. Visit Foresite Capital’s Facebook page for more information.
About Jim Tananbaum
Jim has continued to appear on the Midas List owing to his major investments in the healthcare industry. He has invested in unicorn Intarcia Therapeutics and Juno Therapeutics. In December of 2014, the latter went public as the largest biotech IPO. Notably, Tananbaum has invested in Puma Technology.
The executive is credited for leading a Series B funding that raised $80 million in 2015 for Aimmune Pharmaceuticals, a leading food allergy immunotherapy treatment. Tananbaum is an alumnus of Massachusetts Institute of Technology, Harvard University and Yale University.